Milica Enoiu
Vifor Pharma Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Milica Enoiu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:29 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05885737 · Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe PruritusVifor Fresenius Medical Care Renal Pharma · completed · Uremic Pruritus · study director
- Ph1NCT05885763 · Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on HaemodialysisVifor Fresenius Medical Care Renal Pharma · completed · End Stage Renal Disease on Hemodialysis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:29 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- 32 citationsRCR 1.4
- Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.Invest New Drugs · 201731 citationsRCR 1.0
- Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.Br J Haematol · 201610 citationsRCR 0.3
- Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.Support Care Cancer · 20179 citationsRCR 0.3
- 8 citationsRCR 2.6
- Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease.Pediatr Nephrol · 20217 citationsRCR 0.7